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ABSTRACT 
OBJECTIVE:  To provide an update to the 2008 consensus statements for the diagnosis and 
management of critical illness related corticosteroid insufficiency (CIRCI) in adult and pediatric 
patients.                                                                                                                                      
PARTICIPANTS: A multi-specialty task force of 16 international experts in critical care 
medicine, endocrinology, guideline methods, and members of the Society of Critical Care 
Medicine and the European Society of Intensive Care Medicine.   
DESIGN/METHODS: The recommendations were based on the summarized evidence from the 
2008 document in addition to more recent literature from an updated systematic review 
incorporating relevant studies from 2008 to 2017 and formulated using the Grading of 
Recommendations Assessment, Development, and Evaluation (GRADE) methodology.  The 
strength of each recommendation was classified as strong or conditional and the quality of 
evidence was rated from high to very low based on factors that included the individual study 
design, risk of bias, consistency of the results, and the directness and precision of the evidence.  
Recommendation approval required agreement from at least 80% of the task force members.   
RESULTS:  The task force was unable to reach agreement on a single test that can reliably 
diagnose CIRCI although the delta cortisol (change in baseline cortisol at 60 minutes of < 9 
mcg/dL) after cosyntropin (250 mcg) administration and a random plasma cortisol of < 10 
mcg/dL may be used most commonly by clinicians.  We suggest against using plasma free 
cortisol or salivary cortisol level over plasma total cortisol (conditional, very low quality of 
evidence).  For treatment of specific conditions, we suggest using intravenous (IV) 
hydrocortisone <400 mg/day for at >3 days at full dose, in patients with septic shock that is not 
responsive to fluid and moderate to high dose vasopressor therapy (conditional, low quality of 
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evidence). We suggest against using corticosteroids in adult patients with sepsis without shock 
(conditional recommendation, moderate quality of evidence).  We suggest the use of IV 
methylprednisolone 1 mg/kg/day in patients with early moderate to severe acute respiratory 
distress syndrome (PaO2/FiO2 < 200 and within 14 days of onset) (conditional, moderate quality 
of evidence).  Corticosteroids are not suggested for patients with major trauma (conditional, low 
quality of evidence).  
CONCLUSIONS: Evidence-based recommendations for the use of corticosteroids in critically 
ill patients with sepsis and septic shock, acute respiratory distress syndrome, and major trauma 
have been developed by a multispecialty task force. 
 
Key Words: corticosteroids; glucocorticoids; critical illness; sepsis; septic shock; acute 
respiratory distress syndrome; major trauma   
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Introduction 
Critical Illness Related Corticosteroid Insufficiency (CIRCI) is a concept that was first 
introduced in 2008 by an international multidisciplinary task force convened by the Society of 
Critical Care Medicine (SCCM) to describe impairment of the hypothalamic pituitary axis (stress 
response) during critical illness (1).  CIRCI is characterized by dysregulated systemic 
inflammation resulting from inadequate intracellular glucocorticoid-mediated anti-inflammatory 
activity for the severity of the patient’s critical illness.  The putative symptoms of CIRCI are 
listed in Table 1.  CIRCI is associated with increased circulating levels of biological markers of 
inflammation and coagulation over time, morbidity, length of intensive care unit (ICU) stay and 
mortality.  Given the growing body of evidence that CIRCI occurs across a broad spectrum of 
critical illness, an understanding of the pathogenesis and treatment of CIRCI is important to all 
critical care providers.   
Two emerging themes required that we revisit the concept, diagnosis and management of 
CIRCI: (1) The clear recognition of the importance of evidence-based approaches to patient care 
to enhance quality, improve safety and establish a clear and transparent framework for service 
development and health-care provision; (2) The widespread use of corticosteroids in critically ill 
patients, highlighting the need for a valid, reliable and transparent process of evaluation to 
support key decisions.  
Against this background, the Society of Critical Care Medicine (SCCM) and the 
European Society of Intensive Care Medicine (ESICM) have updated the 2008 guidelines for the 
diagnosis and treatment of CIRCI.  In addition to a rigorous approach in applying GRADE 
methodology, the recommendations in this document focus on patient-important outcomes and 
utility for everyday practicing clinicians.  It was not intended to define a standard of care, and 
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should not be interpreted as one.  As with any clinical practice guideline, it should not be 
interpreted as prescribing an exclusive course of management.  The guideline covers CIRCI in 
critically ill children and adults.  It does not cover chronic adrenal insufficiency, and does not 
cover neonates, because the guideline panel felt these areas represented separate areas of 
expertise.  This guideline focuses on the three disorders that most clinicians link CIRCI to: 
sepsis/septic shock, acute respiratory distress syndrome (ARDS) and major trauma. 
Composition of the Guideline Development Group 
A multispecialty task force of international experts in critical care medicine, 
endocrinology and guideline methods was convened from the membership of the SCCM and the 
ESICM.  The first in-person meeting was held during the SCCM Critical Care Congress in San 
Francisco, CA in January 2014 and was followed by several teleconferences and electronic-
based discussion at regular intervals and another three in-person meetings during the annual 
SCCM Critical Care Congress in January 2015, February 2016, and January 2017.  Members 
who were unable to participate in the in-person meetings were provided opportunity for 
electronic feedback and meeting updates were circulated. 
Conflict of interest policy 
We required all guideline task force members to fill out a detailed Declaration of Interest 
Statement including all current and future financial conflicts of interest (COI) as well as past 
interest restricted to the two years before joining the guideline development process.  No task 
force members reported any financial COI related to the development and writing of the 
guideline.  All members were allowed to participate in all the discussions and have equal weight 
in formulating the statements or in voting.  All were allowed equal involvement in data 
extraction and writing the rationales.  We also allowed members to exclude themselves from 
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discussion and voting around specific questions if they felt significant academic COI.  There was 
no input or funding from industry to produce this guideline. The COI forms are available from 
the SCCM and ESICM and are updated on a regular basis.   
Question Development  
The task force members developed a list of questions that were structured in Population, 
Intervention, Comparison, and Outcome (PICO) format regarding the diagnosis and treatment of 
CIRCI in various clinical conditions (Appendix 1).  The methods chair (BR) assisted in 
developing the PICO questions, i.e. framing the clinical questions into a searchable format.  This 
required careful specification of the patient group (P), the intervention (I), the comparator (C) 
and the outcomes (O) for intervention questions and the patient group, index tests, reference 
standard and target condition for questions of diagnostic test accuracy.  For each question the 
task force agreed upon explicit review question criteria including study design features.  Some of 
these questions were previously addressed in the 2008 guidelines (1) and required updates of the 
evidence summaries whereas others required de novo systematic reviews. 
Assessment of the Relative Importance of the Outcomes 
For each intervention question, a list of outcomes was complied, reflecting both benefits 
and harms of alternative management strategies.  Outcomes (as perceived from the perspective of 
a patient) were ranked from “low” to “critical” importance and agreed upon through consensus 
of the task force members (Appendix 2). Ranking outcomes by their relative clinical importance 
helps to focus on those that are most relevant to patients and may lead to improved clarification 
during potential disagreements in decision making.  
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Searching for Evidence  
Sources 
The information technologists (based at McMaster University, Hamilton, Ontario) 
searched The Cochrane Database of Systematic Reviews, DARE, CENTRAL and Medline for all 
PICO questions on diagnosis and treatment.  All searches were updated through May 2017.  The 
search strategies combined subject headings and text words for the patient population, index test 
and target condition for the diagnostic questions and subject headings and text words for the 
population and intervention for the intervention questions (Appendix 1).  
If a previous meta-analysis of high quality was identified which addressed one of the 
PICO questions, this was used or updated to incorporate new evidence since its publication.  
Search and screening results were provided to the task force to ensure no important trials were 
missed or erroneously included. 
Reference lists from included publications were screened to identify additional papers. 
The methods chair also searched guideline databases and organizations including the National 
Guideline Clearinghouse, Guidelines International Network, Guidelines Finder, Centre for 
Reviews and Dissemination, National Institute for Health and Care Excellence, and professional 
critical care and endocrinology societies for guidelines to screen the reference lists.  
Selection of studies for inclusion 
The information technologists screened all titles and abstracts to discard the clearly 
irrelevant articles.  Task force members completed a second screening.  References were 
allocated to pairs of reviewers for evaluation of eligibility.  All abstracts that did not meet the 
inclusion criteria were discarded.  Any discrepancies at this stage were resolved by group 
consensus.  All pairs of reviewers, with help from the methods support team, retrieved full texts 
of potentially relevant studies and examined them independently for eligibility. Any 
7 
 
  08-08-17 
discrepancies were resolved by consensus.  
 
Data extraction and critical appraisal of individual studies 
For each included study, we collected relevant information on design, conduct, risk of 
bias, and relevant results.  For each question, the methodologist extracted all individual study 
data and produced (when pooling was judged to be appropriate) forest plots by outcome.  All 
analysis was done using Review Manager (RevMan) [Computer program]. Version 5.3. 
Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. 
 Risk of bias of the included studies was evaluated using various validated checklists, as 
recommended by the Cochrane Collaboration (2).  These were AMSTAR for Systematic 
Reviews (3), the Cochrane Risk of Bias tool for randomised controlled trials (4), and the 
Newcastle-Ottawa scale for cohort and case-control studies (5). 
Evidence Profiles 
Evidence summaries for each question were prepared by the methodologist following the 
GRADE approach (6) using the GRADEpro Guideline Development Tool online software 
(www.gradepro.org).   
The evidence profiles include the summary – pooled or narrative - outcome data, an 
absolute measure of intervention effect when appropriate, the importance of the outcome and the 
summary of quality of evidence for each outcome.  Evidence proﬁles were constructed by the 
methodologist and reviewed and conﬁrmed with the rest of the task force members.  
Rating the Quality of the Evidence for Each Outcome across Studies  
In accordance with GRADE, the task force initially categorized the quality of the 
evidence for each outcome as high if it originated from randomized controlled trials (RCTs) and 
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low if it originated from observational data.  We subsequently downgraded the quality of the 
evidence one or two levels if results from individual studies were at serious or very serious risk 
of bias, there were serious inconsistencies in the results across studies, the evidence was indirect, 
the data were sparse or imprecise or publication bias was thought to be likely.  If evidence arose 
from observational data, but effect sizes were large, there was evidence of a dose-response 
gradient, or all plausible confounding would either reduce a demonstrated effect or suggest a 
spurious effect when results showed no effect, we upgraded the quality of the evidence. By 
repeating this procedure, we obtained an overall quality of the evidence for each outcome and 
each intervention.  
Formulating Statements and Grading Recommendations  
Actionable Recommendations 
After the evidence summary tables and evidence profiles were prepared, revised and 
approved by the task force, the recommendations were finalized.  All recommendations were 
developed based on the GRADE evidence profiles for each recommendation.  Each of the 
following factors were considered in recommendation development: the quality of the evidence, 
the balance of desirable and undesirable consequences of compared management options, the 
assumptions about the patient’s values and preferences associated with the decision, the 
implications for resource use and health equity, the acceptability of intervention to stakeholders 
and the feasibility of implementation.  Recommendations and their strength were decided by 
consensus. Committee members unable to join the face-to-face meetings or teleconferences were 
provided opportunity for input electronically.  The entire committee agreed on the final wording 
of each recommendation and rationale with further qualifications for each recommendation (e.g., 
subgroup considerations, justification, implementation considerations).  
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Each recommendation was designated either “strong” or “conditional” according to the 
GRADE approach (7).  As outlined by GRADE, we used the phrasing “we recommend” for 
strong recommendations and “we suggest” for conditional (synonymous with the older 
terminology ‘weak’) recommendations (Table 2).  The implications of the strength of the 
recommendations for patients, clinicians, and policy makers are shown in Table 3. 
Writing Rationale 
We collated the actionable recommendations and the clinical advice for each of the 
clinical questions in separate chapters structured according to a specific format.  Each question 
resulted in one or more specific boxed statements.  Within each recommendation the strength 
was indicated as strong or conditional and the quality of the supporting evidence as high, 
moderate, low or very low (Table 2).  
All statements are followed by advice for clinical practice where relevant and the 
rationale.  The rationale contains a brief section on the relevant background and justification of 
the topic, followed by a short narrative review of the evidence. 
External review 
External peer review was provided through the Board of Regents of the American 
College of Critical Care Medicine, the Councils of the SCCM and ESICM, and the editorial 
boards of Critical Care Medicine and Intensive Care Medicine.  Two international experts in 
endocrinology (George P Chrousos, MD and Stefan R Bornstein, MD) also reviewed the final 
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Recommendations for Diagnosis of CIRCI  
1. Is total cortisol response to synthetic adrenocorticotropic hormone [ACTH] (cosyntropin) 
superior to random plasma total cortisol for the diagnosis of CIRCI? 
Recommendation: The task force makes no recommendation regarding whether to use 
delta cortisol (change in baseline cortisol at 60 minutes of < 9 µg/dL) after cosyntropin (250 
µg) administration or a random plasma cortisol of < 10 µg/dL for the diagnosis of CIRCI. 
Rationale: 
The 2008 guidelines suggested that the diagnosis of CIRCI is best made by a delta total 
serum cortisol of < 9 µg/dL after i.v. cosyntropin (250 µg) administration or a random total 
cortisol of < 10 µg/dL (1).  However, to date, clinicians have not adopted these diagnostic 
criteria in their routine practice.  Moreover, the latest Surviving Sepsis Campaign guidelines 
suggest not using the ACTH stimulation test to select patients with septic shock that may be 
treated with hydrocortisone (8).  Nevertheless, a recent guideline from the Endocrine Society 
confirmed that the high dose (250 μg) ACTH stimulation test is superior to other existing 
diagnostic tests to establish the diagnosis of primary adrenal insufficiency with peak cortisol 
levels below 18 μg/dL (assay dependent) at 30 or 60 minutes indicating adrenal insufficiency (9). 
We found one single center randomized trial that compared low dose ACTH (1 µg) 
stimulation test to total random cortisol to diagnose adrenal insufficiency in 59 adults with septic 
shock (10).  When compared to total random cortisol, the low dose ACTH test was better able to 
predict a longer duration of vasopressor requirement and hemodynamic response to 
corticosteroids.  Similarly, prospective cohort studies in adults with or without sepsis (11) and in 
patients with multiple trauma (12) found that patients with CIRCI, i.e. total cortisol levels <10 
µg/dl or delta cortisol <9 µg/dl, had poorer outcomes than patients without CIRCI.  Likewise, a 
11 
 
  08-08-17 
large multicenter prospective cohort study found that critically ill children with a delta cortisol 
<9 µg/dl after the low dose ACTH stimulation test required higher dose and prolonged treatment 
with catecholamines, higher fluid amount, and had a higher mortality rate (13).  See Appendix 3 
for evidence profile. 
Owing to the potential for risk of bias in study design with only one single center 
unblinded randomized trial and few prospective cohort studies and due to imprecision related to 
low numbers of patients included, we downgraded the quality of evidence to low.  The task force 
members after two rounds of voting could not reach a consensus (>80% agreement) on whether 
the ACTH stimulation test is superior to random cortisol for the routine diagnosis of CIRCI.  
Due to the broad spectrum of abnormalities that may cause CIRCI, from altered metabolism to 
tissue resistance, the task force thought it is unlikely that a single test can reliably diagnose 
CIRCI independent of its mechanisms.  
 
2. Is plasma free cortisol level superior to plasma total cortisol level for the diagnosis of CIRCI? 
Recommendation: We suggest against using plasma free cortisol level as compared to 
plasma total cortisol for the diagnosis of CIRCI (conditional recommendation, very low 
quality of evidence). 
Rationale 
Free cortisol is the bioactive form of cortisol.  Critically ill patients often present with 
low serum concentrations of cortisol binding globulin (CBG) and hypoalbuminemia.  In patients 
with low serum concentrations of cortisol ligands, serum total cortisol levels may not predict 
serum free cortisol levels (14). 
We found no randomized trial that compared serum total versus free cortisol levels to 
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diagnose CIRCI.  Since the 2008 Task Force recommendations, a prospective study of 112 
critically ill adults with treatment-insensitive hypotension, found a good correlation between 
serum concentrations of free and total cortisol before and after 250 µg ACTH stimulation testing 
(15).  These findings suggested that using total cortisol levels after ACTH testing is sufficient in 
critically ill adults.  Another prospective cohort study of 69 critically ill patients to assess the 
time course of serum cortisol levels, found that levels of both free and total cortisol predicted 
clinical outcomes (16).  Another prospective cohort study of 29 adults with septic shock found 
remarkable differences between the serum concentrations of free versus total cortisol levels both 
over time and in response to 1 µg ACTH (17). See Appendix 3 for evidence profile. 
Measuring serum free cortisol levels requires cumbersome techniques that are unlikely to 
be available in all hospital laboratories and unlikely to provide a rapid turnaround time.  There 
were few low quality observational studies with inconsistent findings.  Thus, the task force 
suggested against measuring plasma free cortisol level over plasma total cortisol level in patients 
with suspected CIRCI.    
3. Is salivary free cortisol level superior to plasma total cortisol level for the diagnosis of CIRCI? 
Recommendation: We suggest against using salivary as compared to serum cortisol for 
diagnosing CIRCI (conditional recommendation, very low quality of evidence). 
Rationale: 
 
Cortisol levels are used in an attempt to identify septic patients with CIRCI.  Most studies 
have used total serum cortisol levels to evaluate adrenal function.  However the disadvantage of 
using total serum cortisol is that 90% are linked to CBG and albumin.  In certain patient 
populations such as those with cirrhosis, the synthesis of these proteins is reduced and can lead 
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to an overestimation of the prevalence of adrenal insufficiency (18).  Moreover, in critically ill 
patients, the correlation between free serum and total serum cortisol levels was only 55% to 60% 
(14).   
A few studies evaluated the use of salivary cortisol as a measure for adrenal 
insufficiency.  In one study, free cortisol level was more strongly correlated with salivary than 
with serum total cortisol in 88 cirrhotic patients (Spearman coefficient =0.91 vs. 0.76, 
respectively, p <0.001) (19).  In contrast, in a study of 57 patients with septic shock, there was no 
significant difference between free serum cortisol and salivary cortisol levels (p=.28) (20).  In 
addition, the correlation between salivary cortisol and total serum cortisol levels was very good 
(80%).  Unbound plasma cortisol can be calculated using total serum cortisol and CBG 
measurements (21, 22).  See Appendix 3 for evidence profile. 
The evidence demonstrating any benefit of using salivary cortisol over serum cortisol is 
extremely limited.  Although salivary cortisol may be more closely correlated with free cortisol 
than total cortisol, there is no study that has demonstrated that using salivary cortisol to diagnose 
CIRCI in critically ill patients leads to improved patient outcomes.  Furthermore, the practicality 
and feasibility of using salivary cortisol is questionable given that it is tested by enzyme 
immunoassay which may not be routinely available at most centers.  Additionally, there are 
implementation concerns as in the Estrada-Y-Martin study (20) in that of the 57 patients, 19 were 
excluded as three initial samples did not provide any saliva, and 16 were eliminated because of 
insufficient saliva or blood contamination.  The task force therefore felt that using salivary 
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4. Is the 1 µg ACTH stimulation test superior to the 250 µg ACTH test for the diagnosis of 
CIRCI? 
Recommendation: We suggest that the high dose (250 µg) as compared with the low dose (1 
µg) ACTH stimulation test be used for the diagnosis of CIRCI (conditional 




The high dose (250 µg) ACTH stimulation test remains the most popular diagnostic test 
for adrenal insufficiency.  However, this supraphysiologic dose of ACTH may result in 
significant stimulation of the adrenocortical cells in patients with proven adrenal insufficiency.  
Therefore, to increase the sensitivity of this diagnostic test, low dose (1 µg) ACTH was 
suggested.  The high dose ACTH test is easy to perform and safe.  The low dose ACTH test 
requires some preparation at the bedside as the commercial ampules contain 250 µg of ACTH.  
A recent meta-analysis of 30 studies involving 1209 adults and 228 children, found that 
for secondary adrenal insufficiency, the high and low dose ACTH test had similar diagnostic 
accuracy (23).  The likelihood ratio (LR) of a positive test for adults was 9.1 and 5.9 for the high 
and low dose ACTH test, respectively, and 43.5 and 7.7 respectively, for children.  However, 
both tests had low sensitivity as suggested by the suboptimal LR of a negative test (adults: 0.39 
and 0.19 for the high and low dose ACTH test, respectively; children: 0.65 and 0.34, 
respectively).  A prospective cohort study of 74 adults with septic shock found that the delta 
cortisol using the low and high dose ACTH test was equally accurate in predicting vasopressor 
dependency and mortality (24).  Likewise in a prospective multicenter cohort study of critically 
ill children, the low and high dose ACTH test showed similar accuracy in the prediction of 
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clinical outcomes (13). See Appendix 3 for evidence profile. 
Owing to easier practical modalities and the comparable accuracy of the low and high 
dose ACTH test, the task force suggested using the high dose rather than the low dose ACTH test 
for the diagnosis of CIRCI. 
5. Is hemodynamic response to hydrocortisone (50 to 300 mg) superior to the 250 µg ACTH 
stimulation test for the diagnosis of CIRCI? 
Recommendation: We suggest the use of the 250 µg ACTH stimulation test rather than the 
hemodynamic response to hydrocortisone (50 to 300 mg) for the diagnosis of CIRCI 




First reports on low-dose corticosteroids in human septic shock hypothesized that 
hemodynamic improvement unmasks adrenocortical insufficiency (25, 26).  Hydrocortisone was 
found to improve the vasopressor response to norepinephrine in septic patients, this effect being 
more marked in patients with CIRCI (27).  Arterial hypotension may serve as a useful marker of 
inadequate corticosteroid activity, although not all patients with septic shock may have CIRCI 
(28).  
No studies are presently available that directly address this specific question.  CIRCI 
diagnosed with the 250 µg ACTH stimulation was associated with faster shock resolution in two 
studies (29, 30).  In contrast, the CORTICUS trial found a similar hemodynamic response to 
corticosteroids in patients with or without CIRCI (31).  The recent Hydrocortisone for Prevention 
of Septic Shock (HYPRESS) trial also did not find a difference in the development of septic 
shock in the presence or absence of CIRCI (32). However, in the HYPRESS trial only a limited 
number of patients were screened for having CIRCI altering the reliability of these data. See 
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Appendix 3 for evidence profile. 
Earlier shock resolution has been shown to lead to lower mortality (33). However, no 
studies compared the prognostic value of hemodynamic response versus 250 µg ACTH test for 
the diagnosis of CIRCI.  Meta-analyses examined only different mortality rates with 
corticosteroid treatment between those with and without documented CIRCI (34).  Thus, the task 
force could only recommend the use of the 250 µg ACTH stimulation test to diagnose CIRCI.  
 
6. Is corticotropin level superior to 250 µg ACTH test for the diagnosis of CIRCI? 
Recommendation: We suggest against using corticotropin levels for the routine diagnosis of 
CIRCI (conditional recommendation, low quality of evidence). 
Rationale 
Plasma corticotropin level is the result of corticotropin release from the anterior pituitary 
gland into the systemic circulation.  Normally, plasma concentrations of corticotropin and 
cortisol change in opposite directions.  In primary adrenal insufficiency, plasma cortisol level is 
low and plasma corticotropin level is high.  In hypopituitarism, plasma corticol level is low and 
corticotropin level is low or normal.  During critical illness, plasma corticotropin levels have 
been variably found to be low, normal or high and likely follow a dynamic pattern with 
transiently elevated levels and subsequent decline over weeks after the initial insult (1).  We did 
not find any study that compared the diagnostic accuracy of corticotropin level as compared to 
the ACTH stimulation test.  
Owing to the complexity of measuring plasma level of corticotropin, the task force 
deemed that it is not feasible in most institutions to obtain a corticotropin level with a turnaround 
time to have an impact on the acute management of the critically ill.   
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Recommendations for Corticosteroid Use in Critical Care Conditions 
Sepsis 
A. Among hospitalized adult patients with sepsis without shock, should corticosteroids be 
administered to improve survival and other clinically relevant endpoints? 
Recommendation: We suggest against corticosteroid administration in adult patients with 
sepsis without shock (conditional recommendation, moderate quality of evidence). 
 
Rationale: 
Sepsis and septic shock are major healthcare problems, affecting millions of people 
worldwide annually, and associated with a mortality rate of 25-30% and high direct and indirect 
costs (35-39).  Pro-inflammatory cytokines have been demonstrated to either suppress cortisol 
response to ACTH or compete with intracellular glucocorticoid function which can result in 
CIRCI in septic patients.  Sepsis-related CIRCI may in turn precipitate organ failure and result in 
lack of response to vasopressor therapy in these patients (40, 41).  Thus, the interest in the 
potential benefit of corticosteroids for the treatment of sepsis has been tested in dozens of 
observational studies and trials for several decades.   
Analysis of 27 RCTs (n=3176) of patients with sepsis with and without shock revealed a 
28-day mortality rate of 29.3% in patients receiving corticosteroids compared to 31.8% in those 
who received placebo (RR 0.87, 95% CI: 0.76-1.0) (42).  The quality of evidence was considered 
low owing to inconsistency in the results and for imprecision.  See Appendix 4 for evidence 
profile. 
A separate analysis of 6 RCTs (n=826) of patients with sepsis without shock revealed a 
28-day mortality rate of 33.8% in patients receiving corticosteroids compared to 30.6% in those 
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who received placebo (RR 1.11, 95% CI: 0.91-1.34) (42).  Hyperglycemia was the most common 
adverse event, and corticosteroids did not increase the risk of secondary infections (RR 1.02, 
95% CI: 0.87-1.20).  The quality of evidence was considered moderate due to imprecision given 
the wide confidence intervals.  See appendix 4 for evidence profile. 
Most recently, the Hydrocortisone for Prevention of Septic Shock (HYPRESS) 
multicenter trial, assigned patients with sepsis (excluding those with shock) to either receive a 
continuous infusion of 200 mg of hydrocortisone for 5 days followed by dose tapering until day 
11 (n = 190) or to receive placebo (n = 190) (33).  The primary outcome was development of 
septic shock within 14 days.  Patients who received hydrocortisone had no difference in rates of 
progression to septic shock within 14 days as compared to placebo (difference, -1.8%; 95% CI: -
10.7% to 7.2%; P = .70).  In addition, there were no significant differences between the 
hydrocortisone and placebo groups for the use of mechanical ventilation (53.2% vs. 59.9%), 
mortality at 28 days (8.8% vs. 8.2%) or up to 180 days (26.8% vs. 22.2%), ICU length of stay 
(median [interquartile range], 8 [5-15] vs. 9 [6-17] days), or hospital length of stay (median 
[interquartile range], 26 [16-46] vs. 25 [16-40] days).  In the hydrocortisone vs. placebo groups, 
21.5% vs 16.9% had secondary infections, 8.6% vs 8.5% had ventilation weaning failure, 30.7% 
vs 23.8% had muscle weakness, and 90.9% vs 81.5% had hyperglycemia.  Based on these 
results, the task force members agreed that corticosteroids may not be beneficial in adult patients 
with sepsis without shock. 
B. Among hospitalized adult patients with septic shock, should corticosteroids be 
administered to improve survival and other clinically relevant endpoints? 
Recommendation: We suggest using corticosteroids in patients with septic shock that is not 
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responsive to fluid and moderate to high dose vasopressor therapy (conditional 
recommendation, low quality of evidence).  
C. Among hospitalized adult patients with septic shock treated with corticosteroids, what is 
the recommended dose and duration of treatment? 
Recommendation: If using corticosteroids for septic shock, we suggest using long course 
and low dose (e.g., IV hydrocortisone <400 mg/day for at ≥3 days at full dose) as compared 
with high dose and short course in adult patients with septic shock (conditional 
recommendation, low quality of evidence). 
 
Rationale: 
The latest Cochrane systematic review of the use of low-dose hydrocortisone for treating 
septic shock included 33 RCTs involving 4,268 patients (42) showed that corticosteroids 
significantly reduced the risk of death at 28 days compared to placebo. Three of these RCTs 
included children and the other 30 trials included only adults.  Survival benefits were dependent 
on the dose of corticosteroids with the lower doses (< 400 mg of hydrocortisone or equivalent 
per day) for a longer duration of treatment (3 or more days at the full dose) better, and on the 
severity of the sepsis.  Furthermore, corticosteroids did not cause harm except for an increased 
incidence of hyperglycemia and hypernatremia but no increased risk of superinfection or 
gastrointestinal bleeding. See Appendix 4 for evidence profile.  
  
A network meta-analysis of 22 trials suggested no clear evidence for the superiority of 
one type of corticosteroids over another in adult patients with septic shock (43).  However, 
hydrocortisone boluses and infusions were more likely than methylprednisolone boluses and 
placebo to reverse shock.   
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Given the consistent effect of corticosteroids on shock reversal and low risk for 
superinfection with low dose corticosteroids, the task force suggests the use of low dose IV 
hydrocortisone <400 mg/day for at least 3 days at full dose, or longer in adult patients with septic 
shock that is not responsive to fluid and moderate to high dose (> 0.1 µg/kg/min of 
norepinephrine or equivalent) vasopressor therapy.  The task force panel was unable to comment 
on pediatric patients with septic shock as the meta-analyses we reviewed did not include enough 
patients in this age-specific population. A pilot RCT (Steroids in Fluid and/or Vasoactive 
Infusion Dependent Pediatric Shock, STRIPES) is currently underway to determine the 
feasibility of a larger RCT to address the role of corticosteroids for the treatment of pediatric 
shock (44).  Since the publication of the Cochrane meta-analysis in 2015, a few small studies of 
early corticosteroid therapy in patients with pediatric septic shock and adult patients with sepsis-
associated ARDS have been published (45-47) but the results are consistent with our current 
recommendations. 
The Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) 
trial enrolled 1,241 adult patients with refractory septic shock from 35 centers in France (48).  
This trial commenced in 2008 and initially included the recombinant form of human activated 
protein C (APC), drotrecogin alfa-activated. The study featured a 2x2 factorial design with 
patients assigned to placebo of hydrocortisone, placebo of fludrocortisone, and placebo of APC; 
hydrocortisone + fludrocortisone and a placebo of APC; placebo of hydrocortisone, placebo of 
fludrocortisone and APC; or hydrocortisone + fludrocortisone + APC. Hydrocortisone was 
administered as a 50 mg i.v. bolus every 6 hours and fludrocortisone as a 50 µg tablet via a 
nasogastric tube once daily. In 2011, APC was withdrawn from the market after failing to 
demonstrate adequate efficacy in other clinical trials (49).  Once APC was no longer available, 
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the study continued without APC arms but with one arm comprised of placebo corticosteroids 
(n=627) and the other arm comprised of hydrocortisone and fludrocortisone combined (n=614).  
Another large RCT (ADRENAL Study) conducted in Australia and New Zealand enrolled 3,800 
patients either to hydrocortisone or to a placebo and although enrolment is completed, results are 
not yet available (50).  In this trial, no ACTH stimulation testing was performed.  The final 
results of these two trials are still pending but once available may further define the role of 
corticosteroids in the setting of sepsis or septic shock. Our recommendations may require re-
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Acute Respiratory Distress Syndrome (ARDS) 
Among hospitalized adult patients with ARDS, should corticosteroids be administered to 
improve survival and other clinically relevant endpoints? 
Recommendation:  
We suggest use of corticosteroids in patients with early moderate to severe acute 
respiratory distress syndrome (PaO2/FiO2 of < 200 and within 14 days of onset) 
(conditional recommendation, moderate quality of evidence).   
 
Rationale 
Acute respiratory distress syndrome (ARDS) represents an important public health 
problem globally and despite advances in supportive care, is associated with a high mortality rate 
(35-45%) (51). ARDS is associated with high costs of inpatient care and significant long-term 
morbidity and resource utilization (52).  In ARDS, prolonged mechanical ventilation is 
associated with increased risk of disability and mortality at one year (53, 54).   
Nine trials have investigated prolonged glucocorticoid treatment in ARDS (46, 55-60). 
One of these trials was in patients with ARDS due to community-acquired pneumonia (59) and 
another was a subgroup analysis of the initial corticosteroid trial in septic shock (60).  These 
trials consistently found that glucocorticoid treatment was associated with a significant reduction 
in markers of systemic inflammation (inflammatory cytokines and/or C-reactive protein levels), 
reduction in the duration of mechanical ventilation by approximately seven days and probable 
reduction in hospital mortality by approximately 7% and 11% in patients with mild and severe 
ARDS, respectively (moderate certainty) (61). All, but two trials (55, 56) investigated treatment 
initiated in early ARDS. Early (< 72 hours) vs. late (>7 days) initiation of treatment of 
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methylprednisolone treatment – when fibroproliferation (62) is still in the early stage of 
development (cellular with predominant type III procollagen) – responds to a lower daily 
methylprednisolone dose (1 mg/kg/day vs. 2 mg/kg/day) and is associated with faster disease 
resolution (61). See Appendix 4 for evidence profile. 
A recent individual patient data (IPD) analysis of the four largest trials (N=322) 
investigating prolonged methylprednisolone treatment in early  (57, 58) and late (on and after 
day 7 of onset) (55, 56) ARDS confirmed trial level data demonstrating benefit with 
corticosteroids for improved survival and decreased duration of mechanical ventilation (61).  
With the exception of hyperglycemia (mostly within the 36 hours following an initial 
bolus), prolonged glucocorticoid treatment was not associated with increased risk for 
neuromuscular weakness, gastrointestinal bleeding, or nosocomial infections (61).  
Hyperglycemia was not associated with increased morbidity.  Two trials reported a significant 
risk reduction for developing shock (56, 59).  
The task force members believed that the quality of the evidence for the effect of 
corticosteroids on mortality was moderate given the serious risk of imprecision related to small 
number of events and confidence interval that approaches no effect.  Some of the included trials 
allowed blinded crossover, two trials were unblinded and four trials had less than 60 patients.   
In summary, the task force suggested that methylprednisolone be considered in patients 
with early (up to day 7 of onset; PaO2/FiO2 of < 200) in a dose of 1 mg/kg/day and late (after 
day 6 of onset) persistent ARDS in a dose of 2 mg/kg/day followed by slow tapering over 13 
days (Appendix 5).  Methylprednisolone is suggested given its greater penetration in lung tissue 
and longer residence time (63). Furthermore, methylprednisolone should be weaned slowly (6-14 
days) and not stopped rapidly (2-4 days) or abruptly as deterioration may occur from the 
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development of a reconstituted inflammatory response.  Finally, glucocorticoid treatment blunts 
the febrile response; therefore, infection surveillance is recommended to promptly identify and 
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MAJOR TRAUMA 
Among hospitalized adult patients with major trauma, should corticosteroids be administered to 
improve survival and other clinically relevant endpoints? 
Recommendation: We suggest against the use of corticosteroids in major trauma 
(conditional recommendation, low quality of evidence). 
Rationale 
Major trauma is the main cause of non-septic systemic inflammatory response syndrome 
(SIRS).  Tissue necrosis, hemorrhage and ischemia-reperfusion injury are the main factors that 
trigger the inflammatory cascade.  CIRCI may be common in severe trauma patients, and is 
associated with uncontrolled inflammation, vasopressor dependency and poor clinical outcomes 
(64).  
We found 19 trials (n=12269) that investigated the effects of corticosteroids on short-
term mortality in adults with multiple trauma.  There were 1691/6286 (26.9%) deaths in the 
corticosteroid group vs. 1401/5983 (23.4%) deaths in the placebo group (RR= 1.00; 95% CI: 
0.89 to 1.13).  Stratified analysis of mortality based on corticosteroid dose (low vs. high) found 
no significant dose effect (test for interaction P=0.73).  The RR of dying was 1.03 (95% CI: 0.86 
to 1.22) in the 10 trials that examined low dose corticosteroid treatment, and 0.98 (95% CI: 0.81 
to 1.18) in the 9 trials on high dose corticosteroids.  Corticosteroid therapy did not increase the 
risk of gastroduodenal bleeding (12 trials, RR=1.22; 95% CI: 0.90 to 1.65) or superinfection 
(n=7 trials; RR=0.93; 95% CI: 0.80 to 1.08).  Two trials examined the effects of hydrocortisone 
(65) and hydrocortisone plus fludrocortisone (66) specifically in trauma-associated CIRCI, as 
defined by a change in baseline cortisol at 60 minutes of < 9 mcg/dL after cosyntropin (250 mcg) 
administration.  In the first trial (n=113 multi-trauma patients with CIRCI), hydrocortisone 
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therapy prevented the development of hospital acquired pneumonia by day 28 (HR, 0.47; 95% 
CI, 0.25-0.86) and increased by 6 days (95% CI, 2-11) the number of mechanical ventilation-free 
days.  In the second trial (n=267 head trauma patients with CIRCI), the HR for hospital-acquired 
pneumonia with corticosteroids vs. placebo was 0·80 (95% CI 0·56–1·14).  In this trial, there 
was no interaction between response to corticosteroid therapy and CIRCI status. See Appendix 4 
for evidence profile. 
The largest trials which primarily drive the signal for mortality outcome were at low risk 
of bias, and stratified analysis found no dose effect.  Although the type of patients, 
corticosteroids, dose and duration varied fairly across trials, there was no evidence for significant 
inconsistency in the results.  Although it appears that corticosteroids have no effect on mortality 
in trauma patients, the imprecision of pooled results does not allow excluding a potential for 
benefit or harm from corticosteroid therapy.  The task force members judged the overall quality 
of evidence for this question as being low.  Given the potential for clinically important side 
effects with treatment, the task force made a conditional recommendation against corticosteroids 
for major trauma until further data is available supporting its use. 
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